Drug intelligence / Profile preview

Phenobarbital + Hyoscyamine + Atropine + Scopolamine

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

This drug combination is used to treat stomach or bowel disorders, such as stomach ulcers, irritable bowel syndrome (IBS), and bowel inflammation. It works by relaxing the muscles of the stomach and bowel, reducing cramping. The combination includes **phenobarbital**, a barbiturate with sedative and anticonvulsant properties, and **hyoscyamine**, **atropine**, and **scopolamine**, which are belladonna alkaloids with anticholinergic and antispasmodic effects.

Brand names: DonnatalDonnatal ElixirPB Hyos ElixirQuadrapax ElixirPhenohytro
Other names: Belladonna Alkaloid Combinations and Phenobarbital

Targets

mAChR (Muscarinic acetylcholine receptors)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on Phenobarbital + Hyoscyamine + Atropine + Scopolamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phenobarbital + Hyoscyamine + Atropine + Scopolamine.

Explore the full profile